NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection

Abstract

NVX-CoV2373 (marketed as Nuvaxovid) is a protein-based vaccine against SARS-CoV-2, approved in Canada for adults unable or unwilling to receive an mRNA vaccine Protein-based vaccines have a long history of use that may make them more acceptable to patients who are hesitant to receive mRNA vaccination. 1 NVX-CoV2373 consists of a recombinant spike protein subunit plus adjuvant. It may also be considered for people who are allergic to components of mRNA vaccines (e.g., polyethylene glycol). 2 2 NVX-CoV2373 can be used in a primary series of vaccination NVX-CoV2373 can be administered in a 2-dose primary series or as a heterologous primary series with another approved vaccine against SARS-CoV-2. Doses should be separated by 8 weeks to maximize immune response. 2 3 NVX-CoV2373 may be offered as a boosterAlthough not approved by Health Canada for this indication, the National Advisory Committee on Immunizations recommends NVX-CoV2373 as a booster 6 months after any primary series. 2

Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins

“…SARS-CoV-2 has been the promoter of scientific advancement in the vaccinology field, resulting in the rapid development and approval of new mRNA-based vaccines from Moderna and Pfizer ( 4 , 5 ) and the subsequent approval of protein-based vaccines from Novavax ( 6 , 7 ). These vaccines were developed to direct the immune response to the surface spike (S) protein, which binds to the host cell receptor angiotensin-converting enzyme 2 (ACE2), mediating viral cell entry and infection ( 8 ).…”

Angioedema‐like eyelid edema following the second NVX‐CoV2373 COVID‐19 vaccination

“…NVX‐CoV2373 (Novavax) is a protein‐based vaccine targeting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), and composed of recombinant full‐length, stabilized prefusion spike protein homotrimers that form approximately 30‐nm nanoparticles based on hydrophobic interaction with a central polysorbate‐80 micelle 1 . A two‐dose regimen of the NVX‐CoV2373 administered to adult participants conferred 89.7% protection against SARS‐CoV‐2 infection, 2 and studies evaluating its efficacy against Omicron variant are ongoing 3 . Herein, we report a case displaying angioedema‐like eyelid edema after NVX‐CoV2373 coronavirus disease 2019 (COVID‐19) vaccination.…”

An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines

“…A recent study reported enhanced neutralization of Omicron BA.1 and BA.4/BA.5 following three doses of the NVX-CoV2373 vaccine, with responses similar to three doses of an mRNA vaccine. Evaluation of the vaccine's effectiveness against the Omicron variant is still ongoing ( Bhiman et al, 2022 ; Vohra-Miller and Schwartz, 2022 ). Because of the low vaccination rates or the flow of misleading information about mRNA vaccines in some countries, and due to the use of manufacturing technology similar to what was used in pertussis and influenza vaccines, which have been used routinely in pregnancy, pregnant women may be more accepting of this vaccine ( Parums, 2022 ).…”